CBD Synergies–AX Calming Formula References

  1. Pacher P et al. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013 May;280(9):pp. 1918-43 View Full Paper
  2. McPartland JM et al. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9(3):e89566 View Full Paper
  3. Di Marzo V et al. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008; 29:229–233. View Abstract
  4. Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346: pp. 561-564 View Abstract
  5. Munro S et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: pp. 61-65 View Abstract
  6. Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 992; 258: pp. 1946–1949 View Abstract
  7. Morales P, et al. Molecular targets of the phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:103-131 View Abstract
  8. Citti C et al. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method.J Pharm Biomed Anal. 2016 Sep 5;128:201-209 View Abstract
  9. Turner SE. Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:61-101 View Abstract
  10. Ligresti A. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016 Oct;96(4):1593-659 View Full Paper
  11. Mechoulam R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002 Nov;42(S1):11S-19S. View Abstract
  12. El-Alfy AT et al. Antidepressant-like effect of19 -tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 2010; 95, pp. 434–442 View Full Paper
  13. Ashton CH et al. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011 Oct;124(4): pp. 250-61 View Abstract
  14. Korem N et al. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol. 2016 May 1;27(3): pp. 193-202 View Full Paper
  15. Blessing EM et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct; 12(4): pp. 825–836 View Full Paper
  16. Mandolini GM et al. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335 View Abstract
  17. Soares VP et al. Evidences for the antipanic actions of cannabidiol. Current Neuropharmacology 2017; 15, 291–299 View Full Paper
  18. Crippa JAS et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology 2011; 25, 121–130. View Abstract
  19. Linares IMP et al. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo controlled, crossover study. Front Pharmacol. 2018 Apr 5;9:315. View Full Paper
  20. Möhler H. The GABA system in anxiety and depression and its therapeutic potential Neuropharmacology. 2012 Jan;62(1):42-53. doi: 10.1016/j.neuropharm.2011.08.040. View Abstract
  21. Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry. 2003;64 Suppl 3:21-7 View Full Paper
  22. Abdou AM.  Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans Biofactors. 2006;26(3):201-8 View Abstract
  23. Yoto A. Oral intake of γ-aminobutyric acid affects mood and activities of central nervous system during stressed condition induced by mental tasks. Amino Acids. 2012 Sep;43(3):1331-7. View abstract
  24. Mazzoli R et al. The neuro-endocrinological role of microbial glutamate and GABA signaling. Front Microbiol. 2016 Nov 30;7:1934  View Full Paper
  25. Baldwin D et al. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol. 1995 Jan;9 Suppl 4:41-5 View Abstract
  26. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80 View Full Paper
  27. Haskell CF et al.  The effects of L-theanine, caffeine and their combination on cognition and mood. Biol.Psychol. 2008;77(2):113-122 View Abstract
  28. Kimura K et al. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39–45. View Abstract
  29. Nathan PJ et al. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother. 2006;6(2):21-30. View Abstract
  30. Shi Y. Herbal insomnia medications that target GABAergic systems: a review of the psychopharmacological evidence. Curr Neuropharmacol. 2014 May;12(3):289-302. View Full Paper
  31. Hui KM, et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol. 2002; 64(9): 1415-1424.
  32. Mohebitabar S et al. Therapeutic efficacy of rose oil: A comprehensive review of clinical evidence. Avicenna J Phytomed. 2017 May-Jun;7(3):206-213. View Full Paper
  33. Boskabady MH et al. Pharmacological effects of rosa damascena. Iran J Basic Med Sci. 2011 Jul;14(4):295-307. View Full Paper